Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Windlas Biotech Ltd. ( (IN:WINDLAS) ) has issued an update.
Windlas Biotech Limited has announced amendments to Sub-clause 3.2 of its Windlas Plan 2025, which were approved by the Nomination and Remuneration Committee. These changes aim to provide clarity on the number of stock units that can be granted to employees annually, without altering shareholder-approved limits. The amendments specify that the maximum number of units granted per eligible employee per year shall not exceed 2,09,590 units. This update aligns with regulatory requirements and ensures compliance with applicable laws, with no adverse impact on employee interests.
More about Windlas Biotech Ltd.
Windlas Biotech Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of pharmaceutical products. The company is known for its expertise in producing a wide range of formulations and has a significant presence in the Indian market.
Average Trading Volume: 5,058
Technical Sentiment Signal: Strong Buy
Current Market Cap: 21.28B INR
For detailed information about WINDLAS stock, go to TipRanks’ Stock Analysis page.